Expect Intellectual Fireworks At FDA Advisory Panel On Ezetimibe
You can expect a lot of high-powered intellectual fireworks at next Monday’s FDA advisory panel considering Merck’s application to upgrade the indications for Vytorin and Zetia. Both brands contain the cholesterol-lowering drug ezetimibe, which was studied exhaustively– in many senses of the word– in the IMPROVE-IT trial. The discussion will likely focus on what to do about missing data and how to...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol ezetimibe FDA advisory panel IMPROVE-IT statins vytorin Zetia Source Type: blogs
More News: Cardiology | Cholesterol | Epidemiology | Heart | Medical Ethics | Merck | Statin Therapy | Vytorin | Zetia